首程控股(00697.HK)管理基金引入投資者 合夥企業認繳出資規模增至20.2億人幣
首程控股(00697.HK)公布,去年旗下兩家全資附屬公司包括首元新能及首源投資與其他合夥人簽訂合夥協議成立合夥企業。
合夥企業由首元新能擔任普通合夥人及執行事務合夥人,首源投資、首鋼基金、國家製造業轉型基金、天津創吉、首鋼股份及首新萬泰為有限合夥人,合夥企業的認繳出資總額為16.16億元人民幣。
近日,經首元新能與潛在投資人積極溝通,合夥企業引入北京順義科技創新集團有限公司作為有限合夥人,認繳出資4億元人民幣;同時,首元新能增加認繳出資404萬元人幣。
而在順義科創加入和首元新能增資後,合夥企業認繳出資總額規模由16.16億元增至20.2億元人民幣。(ca/k)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.